glp-1 options for type 2 diabetes and obesity 2025 GLP-1RAs Reduce External Eating Behavior with GLP-1 Therapy for Diabetes and

However, while GLP-1 RAs did not exhibit an increased risk of acute pancreatitis, DPP-4 inhibitors demonstrated a notable risk elevation (rate ratio, 1.75) [53]

The cliff at 65 is about to move That cliff is about to get smaller

Evidence-based guides, dosing tools, treatment comparisons, and a community of thousands who have navigated these exact questions make it the go-to platform for peptide education and support

The STEP 1 extension data showed maintained weight loss at 104 weeks, with participants maintaining an average 13.7% weight reduction from baseline

Mild side effects, such as feeling tired or nauseated, typically subside as the dose equilibrates

Like most GLP-1 medications, they can make you tired, but the timing and intensity may vary slightly based on which drug youre taking